Autoimmune demyelinating disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:35 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Autoimmune demyelinating disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Satralizumab for Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) https://clinicaltrials.eu/trial/study-on-the-effects-of-satralizumab-for-patients-with-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad/ Wed, 29 Apr 2026 14:57:21 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-satralizumab-for-patients-with-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad/ This clinical trial is focused on studying a condition known as Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). This is a rare disorder that affects the nervous system, particularly the brain, spinal cord, and optic nerves. The study is testing a treatment called Satralizumab, which is given as a solution for injection. Satralizumab is being evaluated to see how well it works and how safe it is for people with MOGAD. Some participants will receive Satralizumab, while others will receive a placebo, which looks like the treatment but does not contain the active medicine.

The purpose of the study is to understand the effects of Satralizumab when used alone or alongside other treatments that patients might already be taking. The study will follow participants over a period of time to observe any changes in their condition, particularly looking at the time it takes for a relapse, or return of symptoms, to occur. Participants will receive injections under the skin, and the study will monitor various health indicators, including any side effects and changes in their condition.

Throughout the study, participants will undergo regular check-ups and tests, such as MRI scans, to track the progress of their disease and the impact of the treatment. The study aims to provide valuable information on whether Satralizumab can help manage MOGAD more effectively and improve the quality of life for those affected by this condition. The trial is expected to continue for several years to gather comprehensive data on the treatment’s effectiveness and safety.

]]>